DRIO Stock Overview
Operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
DarioHealth Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$2.60 |
| 52 Week Low | US$0.63 |
| Beta | 1.41 |
| 1 Month Change | -0.39% |
| 3 Month Change | -21.41% |
| 1 Year Change | -54.31% |
| 3 Year Change | -94.23% |
| 5 Year Change | -87.70% |
| Change since IPO | -99.98% |
Recent News & Updates
Slammed 25% DarioHealth Corp. (NASDAQ:DRIO) Screens Well Here But There Might Be A Catch
Nov 17
A Piece Of The Puzzle Missing From DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Climb
Oct 03Recent updates
Slammed 25% DarioHealth Corp. (NASDAQ:DRIO) Screens Well Here But There Might Be A Catch
Nov 17A Piece Of The Puzzle Missing From DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Climb
Oct 03Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 30% Lower
Aug 09Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues
May 31DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 23% Below Their Intrinsic Value Estimate
Feb 16Time To Worry? Analysts Just Downgraded Their DarioHealth Corp. (NASDAQ:DRIO) Outlook
Nov 06Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?
Oct 07Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 28% Lower
Aug 16Need To Know: Analysts Just Made A Substantial Cut To Their DarioHealth Corp. (NASDAQ:DRIO) Estimates
Aug 15DarioHealth Corp. (NASDAQ:DRIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 13DarioHealth (NASDAQ:DRIO) Is Using Debt Safely
Oct 05Need To Know: The Consensus Just Cut Its DarioHealth Corp. (NASDAQ:DRIO) Estimates For 2022
Aug 24DarioHealth Q2 2022 Earnings Preview
Aug 12DarioHealth: Paying 1.6x Equity Value For Cash Flows Priced Into The Future
Jul 29Shareholder Returns
| DRIO | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 12.7% | -1.9% | 0.6% |
| 1Y | -54.3% | -1.3% | 23.7% |
Return vs Industry: DRIO underperformed the US Healthcare Services industry which returned -1.3% over the past year.
Return vs Market: DRIO underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| DRIO volatility | |
|---|---|
| DRIO Average Weekly Movement | 12.7% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DRIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DRIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 249 | Erez Raphael | www.dariohealth.com |
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems.
DarioHealth Corp. Fundamentals Summary
| DRIO fundamental statistics | |
|---|---|
| Market cap | US$23.70m |
| Earnings (TTM) | -US$32.30m |
| Revenue (TTM) | US$23.05m |
1.2x
P/S Ratio-0.8x
P/E RatioIs DRIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRIO income statement (TTM) | |
|---|---|
| Revenue | US$23.05m |
| Cost of Revenue | US$9.01m |
| Gross Profit | US$14.04m |
| Other Expenses | US$46.34m |
| Earnings | -US$32.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 60.91% |
| Net Profit Margin | -140.11% |
| Debt/Equity Ratio | 49.3% |
How did DRIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:34 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DarioHealth Corp. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Steven Halper | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | Rodman & Renshaw, LLC |
| David Grossman | Stifel, Equities Research |